You are here: Home: Audio Program Guide: BCUC 2 | 2007 Audio: BCUC 2 | 2007
 

Go to interview with Dennis J Slamon, MD, PhD
Go to interview with Sharon Hunt, MD
Go to Roundtable Discussion

To listen to individual tracks, click the on the track you wish to listen to.
To download tracks, right-click on the one you wish to download.
     
Slamon, MD Dennis J Slamon, MD, PhD
Professor of Medicine
Chief, Division of Hematology/Oncology
Director of Clinical/Translational Research
Jonsson Comprehensive Cancer Center
David Geffen School of Medicine at UCLA
Los Angeles, California

  
  Click here to download the entire interview  
Track 1 Rationale for combining trastuzumab with chemotherapy
Track 2 Pathogenesis of cardiac dysfunction associated with trastuzumab
Track 3 Cardiac safety of trastuzumab and chemotherapy
Track 4 Clinical use of anthracyclines in patients with HER2-positive, TOPO II-positive disease
Track 5 Clinical use of anthracyclines in patients with HER2-negative disease
Track 6 Next generation of adjuvant trials for HER2-positive disease

Track 7 Cardiac safety of lapatinib
Track 8 Management of subcentimeter, node-negative, HER2-positive disease
Track 9 Accrual issues with a nontrastuzumab-containing regimen in the ALTTO trial
Track 10 BETH trial: TCH alone or with bevacizumab
Track 11 Combining trastuzumab with docetaxel/cyclophosphamide (TC)
     
Hunt, MD Sharon Hunt, MD
Professor of Cardiovascular Medicine
Medical Director of the Post-Cardiac Transplant Program
at Stanford University Medical Center
Palo Alto, California

  
  Click here to download the entire interview  
Track 1 Potential cardiac complications later in life from breast cancer treatment
Track 2 Quality-of-life issues associated with congestive heart failure (CHF)
Track 3 Cardiac transplantation secondary to anthracycline-related cardiomyopathy
Track 4 Advances in CHF management
Track 5 Pathophysiology of CHF
Track 6 Influence of hypertension on cardiac function

Track 7 Follow-up and monitoring of patients who have received adjuvant trastuzumab or anthracyclines
Track 8 Preemptive therapy in women with early evidence of left ventricular dysfunction
Track 9 Eligibility criteria for the adjuvant trastuzumab clinical trials
Track 10 Diastolic heart failure in women
Track 11 Cardiac toxicity in the adjuvant trastuzumab trials
Track 12 Long-term risk of cardiac toxicity with adjuvant trastuzumab and an anthracycline
Track 13 Impact of diet and exercise on risk of cardiac disease
     
  Roundtable Discussion


  
  Click here to download the entire dicussion  
Track 1 Case 1: A 36-year-old pregnant woman with a 2.7-cm, node-positive, ER-negative, PR-negative, HER2-positive infiltrating ductal carcinoma
Track 2 Time course of cardiotoxicity associated with trastuzumab and anthracyclines
Track 3 Clinical use of endomyocardial biopsy and biomarkers in the differential diagnosis of heart failure
Track 4 Long-term management of trastuzumab-related heart failure
Track 5 NCCTG-N9831: Efficacy of AC arrowpaclitaxel followed by trastuzumab
Track 6 Echocardiogram versus MUGA scan in the differential diagnosis of heart failure
Track 7 Cardiac safety of trastuzumab with paclitaxel

Track 8 Efficacy of TCH (docetaxel, carboplatin or cisplatin, and trastuzumab)
Track 9 Clinical use of TCH
Track 10 Cardiac safety of TCH
Track 11 Hypertension associated with bevacizumab
Track 12 Management of hypertension in patients receiving anti-angiogenesis agents
Track 13 Preventing declines in ejection fractions associated with cancer therapies
Track 14 Predictive models for risk of CHF
Track 15 Antiproliferative and apoptotic effects of statins
Track 16 Cardiac tolerability of trastuzumab in combination with bevacizumab
Track 17 Influence of ethnicity on risk of cardiac disease
Track 18 Obesity as an independent risk factor for cardiac disease
Track 19 Elevated ejection fractions in elderly patients
Track 20 Eligibility criteria for patients enrolled in the adjuvant trastuzumab trials
Track 21 Incorporation of antiplatelet therapy in patients with cardiomyopathy
Track 22 Treatment for patients older than age 75
Track 23 Continuation of cardiac medications in patients with trastuzumab-related CHF
Track 24 Antihypertensive agents for bevacizumab-related hypertension

Track 25 Case 2: A 76-year-old woman with a 2.1-cm, node-negative, ER-positive, PR-positive, HER2-negative
infiltrating ductal carcinoma
Track 26 Competing causes of mortality in older women with breast cancer
Track 27 Efficacy and safety of adjuvant TC
Track 28 Risk of anthracycline-related cardiotoxicity
Track 29 Baseline risk of heart failure in older women
Track 30 Performance status in the elderly and proactivity of therapy
Track 31 Role of adjuvant anthracyclines in women with breast cancer
Track 32 Clinical use of the Oncotype DX™ assay
Track 33 TOPO II amplification and response to anthracycline chemotherapy
Track 34 Fluid retention associated with docetaxel
Track 35 History of myocardial infarction as a contraindication to anthracyclines
Track 36 Case 3: A 50-year-old woman with Stage II (T2N0), hormone receptor-positive, HER2-positive breast cancer
Track 37 Adjuvant therapy for women with smaller, node-negative, HER2-positive tumors
Track 38 Palpitations associated with doxorubicin
Track 39 Patients’ concerns about cardiotoxicity
Track 40 Case 4: A 73-year-old woman with node-positive, ER-positive, PR-positive, HER2- negative breast cancer
Track 41 Clinical use of the nonanthracycline TC regimen
Track 42 Case 5: A 75-year-old woman with Stage IIA, node-positive, hormone receptor-positive, HER2-positive
breast cancer
Track 43 Clinical use of lapatinib in patients who cannot tolerate trastuzumab
Track 44 Cardiac safety of lapatinib
Track 45 Additional cardiac evaluation strategies
Track 46 Scheduling of trastuzumab
Track 47 Duration of therapy with adjuvant trastuzumab
Track 48 Case 6: A 79-year-old woman with a 3-cm, node-positive, ER-positive, PR-positive, HER2-positive breast cancer
Track 49 Benefit from adjuvant hormonal therapy in patients with HER2-positive tumors
Track 50 Adjuvant chemotherapy selection for an elderly patient
Track 51 Case 7: A 30-year-old woman with a 1-cm, ER-positive, HER2-positive breast tumor who has a history
of venous thromboses
Track 52 Echocardiography in the evaluation of patients receiving trastuzumab